Skip to main

Thoracic Surgical Oncology Group

In conjunction with the Fiona and Stanley Druckenmiller Center for Lung Cancer Research at Memorial Sloan Kettering Cancer Center and the AATS, the Thoracic Surgery Oncology Group (TSOG) was formed in 2017 to support a network of North American thoracic surgery clinical trials relevant to physicians and their patients—something that had been missing from the landscape in recent years. The overarching goal of the group is to improve the understanding of thoracic oncologic diseases and enhance patient care through the administration of multi-site trials focused on recent advances in precision medicine, immunotherapy, and intraoperative imaging.

TSOG will actively accrue patients to relevant investigator-initiated clinical trials, as well as select industry-sponsored clinical trials, designed to improve outcomes for patients with thoracic malignancies. Learn more about joining the network and current RFA.

Committee Members


David R. Jones

Memorial Sloan Kettering Cancer Center


Raphael Bueno

Brigham and Women's Hospital


David H. Harpole

Duke University


Ara A. Vaporciyan

The University of Texas MD Anderson Cancer Center

Current Sites

Allegheny General Hospital Cancer Center
Baylor College of Medicine
Brigham and Women’s Hospital
Case Western Reserve University School of Medicine
Centre Hospitalier de l’Université de Montréal (CHUM)
Duke University
Fox Cancer Center
Hospital of Fox Chase Cancer Center
Massachusetts General Hospital
Mayo Clinic Jacksonville
Mayo Clinic Rochester
McMaster University (St. Joseph’s Hamilton)
MD Anderson Cancer Center
Memorial Sloan Kettering Cancer Center
NYU Langone Medical Center
Roswell Park Comprehensive Cancer Center
Rush University Medical Center
Stanford University
The University of Texas MD Anderson Cancer Center
Thomas Jefferson University
University of California Los Angeles
University Hospitals Cleveland Medical Center
University of Michigan
University of Montreal
University of Pennsylvania
University of Pittsburgh
University of Southern California
University of Toronto (UHN)
Vanderbilt University
Washington University in St. Louis
West Virginia University

TSOG 101

Dr. James M. Isbell, MSCI, Memorial Sloan Kettering Cancer Center

“Study to evaluate perioperative circulating tumor DNA as prognostic biomarker in patients undergoing neoadjuvant therapy for resectable non-small cell lung cancer.” —TSOG 101

The aim of this study is to determine the validity of using quantitative ctDNA as a surrogate marker for pathologic treatment response in patients receiving neoadjuvant therapy for stage IIA-IIIB NSCLC who are undergoing curative-intent resection.

The second aim is to determine, in patients with NSCLC, the prognostic value of persistent ctDNA following curative-intent resection for predicting recurrence, disease-free survival, and overall survival.

The third aim is to correlate the percent change in levels of ctDNA to percent change in the SUVmax of the primary tumor on 18-FDG-PET scan before and after neoadjuvant therapy.

TSOG 102

Dr. James Huang, Memorial Sloan Kettering Cancer Center

“Registry trial of active surveillance for multifocal ground glass opacities (GGOs).” —TSOG 102

The primary objective of this study is to determine lung cancer–specific survival at 5 years among patients undergoing active surveillance for GGOs.

The secondary objective is to determine the following endpoints among patients undergoing active surveillance for GGOs: overall survival, freedom from progression (any), freedom from nodal progression, freedom from distant progression, cumulative incidence of intervention (biopsy or resection), cumulative incidence of a new GGO, and cumulative incidence of confirmed lung cancer diagnosis.


Dr. Mara Antonoff, The University of Texas MD Anderson Cancer Center

“The role of multimodality management in risk-stratified patients with lung-limited metastatic colorectal cancer.” —TSOG 103

The primary objectives of this study are to compare recurrence-free survival in patients with “low-risk” lung-limited mCRC undergoing pulmonary metastasectomy with or without perioperative chemotherapy, as well as to compare overall survival in patients with “high-risk” lung-limited mCRC receiving systemic chemotherapy with or without surgical resection.

Additional exploratory objectives involve the evaluation of changes in ctDNA following surgical resection and/or systemic chemotherapy in patients with lung-limited mCRC.

TSOG 104

Dr. Harvey Pass, New York University Langone Medical Center

"A prospective, non interventional, trial
evaluating the diagnostic accuracy of FBLN3
for mesothelioma pleural effusions." —TSOG 104

The primary objective of this study is to
prospectively create a virtual reference
set of pleural effusion samples from
patients referred for treatment of a
pleural effusion which can be used for future
biomarker discovery and validation
The secondary objectives using pleural
effusion samples, will be to calculate the
FBLN3 concentration and compare the
levels between the cohorts collected
including non-mesothelioma benign,
non-mesothelioma malignant, and mesothelioma.
We will determine the AUC using
FBLN3 to distinguish pleural effusions
of mesothelioma vs non mesothelioma

For additional details about TSOG and how to get involved, please contact:

Maria Singh
Project Manager, Memorial Sloan Kettering Cancer Center

Alain Vincent
Clinical Research Manager, Memorial Sloan Kettering Cancer Center

Erin Carroll
Research Project Associate, Memorial Sloan Kettering Cancer Center